Insulin Biosimilars Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028

  • Single User License $3500

Insulin Biosimilars Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028

Status : August, 2020 | Biotechnology | PPT format

Report Digest


Global Insulin Biosimilars Market: Overview 

It is just handful of companies that are into the distribution and manufacturing of most of the insulin used in the developed countries. A number of new market players have developed its insulin making capacities and such a development is based on the methods of modern biotechnology.

The global insulin biosimilars market gathers its momentum from the increasing prevalence of diabetes. According to a report of World Health Organization (WHO), around 422 Mn adults are suffering from diabetes and around 1.5 million people have been killed by diabetes in the 2012. Insulin biosimilar can improve the access to treatment of diabetes mellitus amongst the diabetic patients. It also lessens the cost of treatment. 

The global insulin biosimilars market has been segmented on the basis of type, disease indication, and region. The main objective of providing such a comprehensive report is to provide a deep insight into the market. 

Global Insulin Biosimilars Market: Notable Developments

The global insulin biosimilars market has witnessed quite a few developments over the last few years. These market developments suggest a trend and give an idea about the growth factors of the global insulin biosimilars market. One such development is mentioned below:

  • In 2016, the U.S-based Momenta Pharmaceuticals, Inc. revealed that it has formed a global collaboration agreement with the US-based Mylan N.V. The collaboration is aimed at commercializing, manufacturing, and developing six of Momenta Pharmaceutical’s present biosimilar candidates. The collaboration also comprised ORENCIA, one of its prominent biosimilar candidates. It is used for the treatment of moderate to severe adult psoriatic arthritis, juvenile idiopathic arthritis, and adult rheumatoid arthritis.

Some of the key market players of the global insulin biosimilars market are

  • Eli Lilly and Company
  • H. Boehringer Sohn AG & Ko. KG
  • Novo Nordisk A/S
  • Wockhardt Ltd.
  • Momenta Pharmaceuticals, Inc.
  • Ypsomed AG

Global Insulin Biosimilars Market: Growth Drivers

Rapid Rise in the Prevalence of Diabetes Worldwide Accentuates its Demand

Biosimilar insulins are made in such a way that it remains extremely similar to the original product. With the rise in the number of biosimilar insulin manufacturers, the offering of clinical aid similar to the present analogs of insulin at a more reasonable price has become possible. In addition, many insulin manufacturing firms are likely to lose their patents quite soon, which is likely to offer ample growth opportunities for the global insulin biosimilars market.

Furthermore, low pricing of biosimilar insulin meant for the treatment of diabetes along with its effectiveness is anticipated to open up new vistas of growth for the global insulin biosimilars market. Several companies are emphasizing on the development of medical devices that enable less painful and self delivery of biosimilar insulin. Such a factor is expected to propel the growth of the global insulin biosimilars market. 

Expanding pool of geriatric population with arthritis and growing demand for fast acting insulin analogues is another booster for the market. Increased investment by government agencies on the research and development activities pertaining to insulin biosimilars is providing ample scope of development for the market.

Global Insulin Biosimilars Market: Regional Outlook

In terms of region, the global insulin biosimilar market is split into the key regions of Middle East and Africa, North America, Europe, Asia Pacific, and Latin America. Of all the geographical segments, it is expected that North America will reign over the global insulin biosimilar market in the forthcoming years. High demand for insulin biosimilars amidst increasing prevalence of diabetes is likely to propel growth of the market in years to come.

Asia Pacific is prophesized to come up as a rapidly growing region in the market due to expanding pool of diabetic patients and changing lifestyle of the people. High competitiveness amongst the companies in the region is expected to further lower the price, thereby propelling the market toward growth.

The global insulin biosimilars market is segmented as:

Type 

  • Rapid Acting Biosimilars
  • Long Acting Biosimilars
  • Premixed Biosimilars 

Disease Indication 

  • Type 1 Diabetes
  • Type 2 Diabetes

The study presents a granular assessment and quantitative evaluation of:

  • Key growth factors and prominent trends
  • Size and share of key segments in overall market
  • Key challenges and winning imperatives
  • Factors shaping competitive landscape
  • Insights into how contours of market will change in coming years
  • Technological advances
  • New avenues and imminent investment pockets
  • Regulatory landscape shaping current and future strategies of companies

The region-wise assessment includes market dynamics in:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The study is prepared with the help of an extensive primary and secondary research. Primary research includes but not limited to interactions, interviews, surveys, and events. Opinions of policy makers and industry experts are carefully integrated into the insights to complement primary research. Volumes of secondary data gleaned through renowned paid sources, annual statements, reputed journals, and government documents offer insights into current dynamics and key evolution trajectories the market is likely to assume. The research employs various industry-wide analytics methods and well-established methodologies to ascertain the attractiveness of key segments. Further, it evaluates the lucrativeness of key regions and factors underlying their maturity. The insights notably include a detailed analysis of forces behind vendor differentiation and offers insight into investment-decision making by prominent players.

The report strives to enlighten businesses and industry stakeholders on multiple facets of the growth dynamic of the market, the key of which include answers to:

  • Which key factors will shape the competitive landscape?
  • Which trends will stimulate research and development activities in different geographies?
  • Which are the lucrative growth areas and what is the size of potential they are likely contribute to the overall market?
  • Which disruptions in market growth are likely to come with the new business models?
  • Which are some of the recent overhauls in policies that may change the course of the market significantly?
  • Which are the geographies that will form sizable sources of new streams to new and established players alike?
  • How are top players likely to realign their strategy to counter the forces of competition?
  • Which key strategies emerging players are likely to focus on to consolidate their position?
  • Which changes in end-user preferences might affect the status quo held by the leading players?
  • Which are some of the game-changing innovations influencing the projected share and revenue of the market and its segments?

Note: Utmost care has invariably been taken to present data and arrive at statistics at all the TMR Research reports. Meanwhile, some recent developments and new industry trends may take time to be included in the reports.